Mad Hedge Technology Letter
March 17, 2023
Fiat Lux
Featured Trade:
(HIGHLY BULLISH FOR TECH STOCKS)
(AAPL), (GOOGL), (ARKK)
Up to $2 trillion in liquidity into the banking system should do the job in the financial sector.
This is highly bullish tech shares and the growth-based tech stocks will experience the best windfalls from this psychological and fiscal reset of the American banking system.
It’s true tech stocks did need a little help as 2022 was really a struggle for them, but 2023 has been brighter with the “buy the dip” mentality back with vengeance.
After the gangbuster January, we’ve been waiting for some direction as to what will happen to tech stocks and now we have gotten the signals.
In short, tech stocks will go higher.
Now, I truly believe that the buy-the-dip mentality will become firmly entrenched and investors should dig deep to execute bullish positions as I expect tech stocks to roar ahead.
Many know about the FDIC, SPIC insured deposits of up to $250,000, but the Fed has rolled out the red carpet for the banking system and lent money to the banks that even don’t need it.
Banks borrowed up to $350 billion in cheap loans from the Fed.
Nearly $143 billion went to holding companies for two major banks that failed over the past week, Silicon Valley Bank and Signature Bank, triggering widespread alarm in financial markets.
Ironically, public tech stocks benefited the most from the government helping the financial industry and it was a crypto-biased bank that bled itself to edge of catastrophe.
Although this creates a moral hazard, I am not really in the business to tell someone what is right or what is wrong in terms of systemic risk.
But knowing that the Fed has the backs of the banks and stock market no matter what is highly bullish for tech stocks in the short-term.
This opens up liquidity like a reservoir opening up its water channels.
Expect a lot more capital sloshing around the financial system that will naturally fall into tech stocks from the boring behemoths to the cash-burning peons.
The tide will lift most boats in this situation.
The bank term financing program should be able to inject enough reserves into the banking system to reduce the reserve deficit and reverse the tightening that took place last year.
I anticipate that the new program will be attractive to a wide range of institutions, apart from those currently facing liquidity problems.
The longer this program sustains itself the better for tech stocks.
Say goodbye to quantitative tightening.
The era of balance sheet reduction is now dead as the Fed is too worried to rock the boat.
Going from QT to printing money which is what this discount window effectively was has stunned the market to the upside.
Moving forward, expect rate hike expectations to dissipate and lower bond yields which will contribute to another tech market rally and in turn a lower dollar.
Most of everything will have a high chance to deliver decent tech gains from ARK Innovation ETF (ARKK) to the Apple’s (AAPL) and Google’s (GOOGL) of the world.
When the Fed wants to widen the goalposts this wide, you don’t need Ronaldo to score a goal.
Buy the dip in tech until we truly see a systemic credit risk or if inflation comes back shooting past the first pandemic peak to form a double top.
“I love museums but I don't want to live in one.” – Said Apple CEO Tim Cook
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Global Market Comments
March 17, 2023
Fiat Lux
Featured Trade:
(OIL ISN’T WHAT IT USED TO BE), (USO), (DIG), (DUG)
(A DIFFERENT VIEW OF THE US)
CLICK HERE to download today's position sheet.
Virtually every analyst has been puzzled by the endless weakness in oil prices (USO), (DIG), (DUG), which have been in a downward spiral for more than a year. Since Russia first invaded Ukraine, the price of Texas tea has collapsed from $132 to $66 a barrel.
In fact, oil ain’t what it used to be.
The first chart below shows the number of barrels of oil needed to generate a unit of GDP, which has been steadily declining for 40 years. The second reveals the percentage of hourly earnings required to buy a gallon of gasoline in the US, which has been mostly flat for three decades, although it has recently started to spike upwards.
The bottom line is that conservation, the rollout of more fuel-efficient vehicles and hybrids, and the growth of alternatives, are all having their desired effect. Notice how small all the new cars on the road are these days, many of which get 40 mpg with conventional gasoline engines.
As for my own household, it has gone all electric. Some 15% or all the new cars sold in the US are EVs, which don’t use oil at all, except for a tiny amount of grease on the wheels and suspension
Developed countries are getting six times more GDP growth per unit of oil than in the past, while emerging economies are getting a fourfold improvement.
The world is gradually weaning itself off of the oil economy. But the operative word here is “gradually”, and it will probably take another two decades before we can bid farewell to Texas tea, at least for transportation purposes.
But the Mileage is Great!
Mad Hedge Biotech and Healthcare Letter
March 16, 2023
Fiat Lux
Featured Trade:
(WHO’S REALLY THE BOSS?)
(ILMN), (AAPL), (TWX), (MDLZ), (CVX)
Carl Icahn—the legendary investor known for toppling corporate behemoths and taking charge of their destinies—has swooped in to save Illumina (ILMN) from its own misguided move.
To salvage what’s left of the promising biotechnology company, he has emerged with a plan for shareholders: halt their recent deal with Grail—a cancer-screening firm that Icahn and his faithful followers want nothing more than to see dropped. Part of his plan is to nominate three people to sit on the board of Illumina. The move sent shares of ILMN soaring – no doubt leaving Icahn feeling pretty victorious himself.
For additional background, Icahn isn’t an ordinary businessman and investor. He is the founder, chairman, and majority shareholder of Icahn Enterprises, a diversified conglomerate holding company based in New York City, formerly American Real Estate Partners. He is one of the world's most successful and influential investors, having made billions through his investments in companies such as Apple (AAPL), Time Warner Inc. (TWX), RJR Nabisco (now Mondelez (MDLZ)), and Texaco (CVX). His extensive corporate takeover activities have resulted in him being dubbed "The King of Corporate Raiders."
As an activist investor, he is an individual or a member of a group of investors who uses their financial resources to directly influence the actions and decisions of organizations, often by purchasing shares in the business.
They often demand changes to corporate structure and strategy changes, board composition, and executive compensation practices. Needless to say, activist investors have a significant impact on a company, as they typically target companies that are undervalued and push for changes that can increase their value.
This is an extremely timely announcement for Illumina since the company’s value plummeted from $70 billion in 2021 to $31 billion in 2023. However, the biotech isn’t going down without a fight.
The acquisition of Grail by Illumina was first announced in September 2020, and it has been a subject of discussion and scrutiny since then. The proposed deal involves Illumina buying out the remaining stake in Grail that it does not already own, for a total of $8 billion in cash and stock.
Illumina believes that its plan to acquire Grail is a significant development in the field of genomics and cancer diagnostics. At the moment, Illumina is a leading provider of genomics technology, while Grail is a biotechnology company focused on developing a blood test for early cancer detection.
The acquisition is expected to create significant synergies between the two companies. Illumina's expertise in genomic sequencing technology combined with Grail's cutting-edge liquid biopsy technology could potentially lead to the development of a powerful and efficient cancer detection tool.
The acquisition has, however, faced some challenges, including regulatory hurdles. The Federal Trade Commission (FTC) expressed concerns that the acquisition could lead to Illumina having a monopoly in the market for sequencing machines, which are used in Grail's liquid biopsy tests. As a result, the FTC filed a lawsuit to block the acquisition.
Despite the challenges, Illumina and Grail remain committed to the deal, and in December 2021, they announced that they had reached a settlement with the FTC. The settlement requires Illumina to sell its existing liquid biopsy technology to a third party and abide by certain conditions to prevent any potential anti-competitive effects of the acquisition.
All things considered, it is undeniable that the acquisition of Grail by Illumina has the potential to revolutionize cancer diagnostics and improve patient outcomes. However, the regulatory hurdles demonstrate the importance of ensuring mergers and acquisitions do not harm competition and ultimately negatively impact consumers.
Overall, Illumina is a promising biotech with much room to grow. It pioneered the development of next-generation sequencing (NGS) technology, which revolutionized the field of genomics. NGS allows researchers to sequence large amounts of DNA quickly and at a lower cost than traditional Sanger sequencing methods.
NGS works by breaking the DNA into small fragments and sequencing them simultaneously. These short reads of DNA are then assembled to create a whole genome. Illumina's NGS technology is based on a proprietary sequencing-by-synthesis method, which uses flourescently labeled nucleotides to detect and record the sequence of DNA bases as they are incorporated into a growing DNA chain.
NGS has many applications in genomics research, including identifying genetic mutations, studying gene expression patterns, and characterizing the microbiome. The technology has also played a critical role in advancing precision medicine and personalized healthcare.
Illumina's pioneering work in NGS has allowed the company to establish a dominant market position in the genomics industry and has driven significant innovation in the field of genomics.
Thanks to this biotech’s products, the cost of a complete human genome analysis dropped from the hundreds of millions range in 2001 to less than $1000 today. More notably, the company projects the price to go lower and be below $200 when it releases its new services.
Being hailed as a market leader is a well-deserved description for the company. After all, Illumina quadrupled its revenues in the past 10 years and continues to deliver decent results.
Icahn’s move to take on Illumina offers a fresh and seemingly more promising perspective regarding the company’s direction. He believes Illumina can unlock value by spinning off non-core businesses, returning cash to shareholders, reducing costs, and improving operational efficiency. However, Illumina's management resisted Icahn's calls for a sale and instead focused on investing in research and development to drive growth.
Still, Icahn's targeting of Illumina is likely driven by his belief that the company is undervalued and not maximizing shareholder value. While it will take time before anything gets resolved, what’s apparent is that Illumina doesn’t hold complete freedom when it comes to decision-making, which would inevitably hurt its future success.
Global Market Comments
March 16, 2023
Fiat Lux
Featured Trade:
(THE MAD HEDGE TRADERS & INVESTORS SUMMIT IS ON MARCH 14-16)
(INVESTORS WILL WIN THE ETF PRICE WAR),
(BIDDING FOR THE STARS)
CLICK HERE to download today's position sheet.
A collection of the 28 best traders and managers in the world, or eight a day, each giving an educational webinar. Back-to-back one-hour presentations are followed by an interactive Q&A. It will be hosted by John Thomas from 9:00 AM sharp each day. Watch for the Pink Floyd music.
It’s a smorgasbord of trading strategies, so pick the one that is right for you. Covering all stocks, bonds, commodities, foreign exchange, precious metals, energy, and real estate. It’s the best look at the rest of 2023’s money-making opportunities you can get anywhere.
Oh, and you will have a chance to win $100,000 in prizes.
To view the schedule and speakers and register NOW, click here.
